Common name
formamide
IUPAC name
formamide
SMILES
C(=O)N
Common name
formamide
IUPAC name
formamide
SMILES
C(=O)N
INCHI
InChI=1S/CH3NO/c2-1-3/h1H,(H2,2,3)
FORMULA
CH3NO
Common name
formamide
IUPAC name
formamide
Molecular weight
45.041
clogP
-0.474
clogS
0.761
Frequency
0.1240
HBond Acceptor
1
HBond Donor
2
Total PolarSurface Area
43.09
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00188 | Flucloxacillin |
|
Anti-Bacterial Agents; Penicillins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antibacterials for Intramammary Use; Beta-Lactamase Resistant Penicillins; Beta-Lactam Antibacterials, Penicillins; Beta-Lactam Antibacterials, Penicillins, for Intramammary Use; CYP3A4 Inhibitors; | Used to treat bacterial infection by susceptible microorganisms. |
| FDBD00190 | Ertapenem |
|
Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbapenems; | For the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to . |
| FDBD00196 | Vindesine |
|
Antineoplastic Agents; Immunosuppressive Agents; Antineoplastic Agents, Phytogenic; Tubulin Modulators; Antineoplastic and Immunomodulating Agents; Vinca Alkaloids and Analogues; CYP3A4 Inhibitors; | For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis. |
| FDBD00200 | Capreomycin |
|
Anti-Bacterial Agents; Protein Synthesis Inhibitors; Antibiotics, Antitubercular; Antibiotics; Antimycobacterials; Antiinfectives for Systemic Use; Drugs for Treatment of Tuberculosis; | Used in the treatment of tuberculosis in combination with other drugs. |
| FDBD00205 | Piperacillin |
|
Anti-Bacterial Agents; Penicillins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials, Penicillins; Penicillins With Extended Spectrum; | For the treatment of polymicrobial infections. |
| FDBD00206 | Dihydroergotamine |
|
Vasoconstrictor Agents; Analgesics; Dopamine Agonists; Analgesics, Non-Narcotic; Anti-migraine Agents; Nervous System; Antimigraine Preparations; Ergot Alkaloids; CYP3A4 Inhibitors; Alpha2 Agonists; Combined Inhibitors of CYP3A4 and P-glycoprotein; | For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. |
| FDBD00220 | Atenolol |
|
Antihypertensive Agents; Adrenergic beta-1 Receptor Antagonists; Sympatholytics; Anti-Arrhythmia Agents; Cardiovascular System; Beta Blocking Agents, Selective; Beta Blocking Agents; Beta Blocking Agents, Selective, and Thiazides; Beta Blocking Agents and Thiazides; | For the management of hypertention and long-term management of patients with angina pectoris. |
| FDBD00224 | Pyrazinamide |
|
Antitubercular Agents; Antimycobacterials; Antiinfectives for Systemic Use; Drugs for Treatment of Tuberculosis; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP3A4 Inhibitors; | For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. |
| FDBD00229 | Aminohippurate |
|
Indicators and Reagents; Diagnostic Agents; Tests for Renal Function and Ureteral Injuries; | Used to measure effective renal plasma flow (ERPF) and to determine the functional capacity of the tubular excretory mechanism. |
| FDBD00230 | Alfuzosin |
|
Antihypertensive Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Genito Urinary System and Sex Hormones; Drugs Used in Benign Prostatic Hypertrophy; Urological Agents; CYP3A4 Inhibitors; | For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia. |
361 ,
37
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 2vl1_ligand_frag_1.mol2 | 2vl1 | 1 | -5.59 | C(=O)N | 3 |
| 1wdn_ligand_frag_3.mol2 | 1wdn | 1 | -5.56 | C(=O)N | 3 |
| 1db5_ligand_frag_4.mol2 | 1db5 | 1 | -5.51 | C(=O)N | 3 |
| 2ntf_ligand_frag_10.mol2 | 2ntf | 1 | -5.51 | C(=O)N | 3 |
| 4pml_ligand_frag_1.mol2 | 4pml | 1 | -5.51 | C(=O)N | 3 |
| 4xmb_ligand_frag_8.mol2 | 4xmb | 1 | -5.51 | C(=O)N | 3 |
| 4tjy_ligand_frag_1.mol2 | 4tjy | 1 | -5.50 | C(=O)N | 3 |
| 4f1q_ligand_frag_4.mol2 | 4f1q | 1 | -5.49 | C(=O)N | 3 |
4319 ,
432
